Cited by 191BRCA gene mutations in cancerMultiple and Secondary Primary CancersBreast Lesions and Carcinomas

Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation in BRCA1 or BRCA2

Open access
Malone, Kathleen E., Begg, Colin B., Haile, Robert W., Borg, Ake, Concannon, Patrick, Tellhed, Lina, Xue, Shanyan, Teraoka, Sharon +10 more·2010·Journal of Clinical Oncology

Abstract

Purpose: Women with breast cancer diagnosed early in life comprise a substantial portion of those tested for BRCA1/BRCA2 mutations; however, little information is available on the subsequent risks of contralateral breast cancer in mutation carriers. This study assessed the risk of subsequent contralateral breast cancer associated with carrying a BRCA1 or BRCA2 mutation. Patients and Methods: In this nested case-control study, patients with contralateral breast cancer diagnosed 1 year or more after a first primary breast cancer (n = 705) and controls with unilateral breast cancer (n = 1,398) were ascertained from an underlying population-based cohort of 52,536 women diagnosed with a first invasive breast cancer before age 55 years. Interviews and medical record reviews were used to collect risk factor and treatment histories. All women were tested for BRCA1/BRCA2 mutations. Relative (rate ratios) and absolute (5- and 10-year cumulative) risks of developing contralateral breast cancer following a first invasive breast cancer were computed. Results: Compared with noncarriers, BRCA1 and BRCA2 mutation carriers had 4.5-fold (95% CI, 2.8- to 7.1-fold) and 3.4-fold (95% CI, 2.0- to 5.8-fold) increased risks of contralateral breast cancer, respectively. The relative risk of contralateral breast cancer for BRCA1 mutation carriers increased as age of first diagnosis decreased. Age-specific cumulative risks are provided for clinical guidance. Conclusion: The risks of subsequent contralateral breast cancer are substantial for women who carry a BRCA1/BRCA2 mutation. These findings have important clinical relevance regarding the assessment of BRCA1/BRCA2 status in patients with breast cancer and the counseling and clinical management of patients found to carry a mutation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2009.24.2495

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Malone, K. E., Begg, C. B., Haile, R. W., Borg, A., Concannon, P., Tellhed, L., Xue, S., Teraoka, S., Bernstein, L., Capanu, M., Reiner, A. S., Riedel, E. R., Thomas, D. C., Mellemkjær, L., Lynch, C. F., Boice, J. D., Anton-Culver, H., & Bernstein, J. L.
Affiliations
  • University of Southern California (US)
  • From the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Preventive Medicine, University of Southern California, Los Angeles; Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute, City of Hope, Duarte; Department of Epidemiology, University of California at Irvine, Irvine, CA; Department of Oncology, Lund...
Venue
Journal of Clinical Oncology
Published
2010-05-10
Volume
28
Issue
14
Pages
2404-2410
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2107243201
Cited by
191
References
36
Citations by year
2026: 5 · 2025: 8 · 2024: 12 · 2023: 9 · 2022: 4 · 2021: 5 · 2020: 18 · 2019: 5 · 2018: 10 · 2017: 14 · 2016: 19 · 2015: 16 · 2014: 11 · 2013: 17 · 2012: 20
FWCI
9.88
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • National Institute on Aging (R01AG014358)
  • National Cancer Institute (R01CA097397, U01CA083178, R01CA131010, R01CA129639)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Keywords
contralateral breast cancer, BRCA1 mutation, BRCA2 mutation, hereditary breast cancer, second primary cancer risk, cumulative risk, age at first diagnosis, mutation carriers, genetic counseling, early-onset breast cancer
MeSH terms
Adult, Age Factors, Breast Neoplasms, Denmark, DNA Mutational Analysis, Female, Humans, Middle Aged, Mutation, Neoplasm Recurrence, Local, Population Surveillance, Risk Factors, Time Factors, United States, Logistic Models, Case-Control Studies, Treatment Outcome, SEER Program, Risk Assessment, BRCA1 Protein, Genetic Predisposition to Disease, BRCA2 Protein, Apoptosis Regulatory Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review